好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer's disease
Aging and Dementia
S2 - (-)
003
Authors/Disclosures
Sebastian F. Von Rosenstiel, MD, PhD (Takeda)
PRESENTER 		Dr. Von Rosenstiel has received personal compensation for serving as an employee of Takeda. Dr. Von Rosenstiel has stock in Takeda.
Sarah Gheuens, MD No disclosure on file
Tianle Chen, PhD Dr. Chen has received personal compensation for serving as an employee of Biogen.
No disclosure on file
Ping Chiao, MD (Biogen Idec) No disclosure on file
No disclosure on file
Christian Von Hehn, MD, PhD No disclosure on file
No disclosure on file
No disclosure on file
Roger Nitsch, MD (University of Zurich, Division of Psychiatry) No disclosure on file
Samantha Budd Haeberlein Samantha Budd Haeberlein has received personal compensation for serving as an employee of Biogen. An immediate family member of Samantha Budd Haeberlein has received personal compensation for serving as an employee of Alkermes. Samantha Budd Haeberlein has received stock or an ownership interest from Biogen.
Alfred W. Sandrock, MD, PhD (Biogen) No disclosure on file